Your browser doesn't support javascript.
loading
Efficacy and safety of tofacitinib in the treatment of ulcerative colitis: real-life experience in Andalusia.
Hernández Martínez, Alvaro; Navajas Hernández, Pilar; Martín Rodríguez, María Del Mar; Lázaro Sáez, Marta; Olmedo Martín, Raúl; Núñez Ortiz, Andrea; Argüelles Arias, Federico; Fernández Cano, María Carmen; Gallardo Sánchez, Francisco; Marín Pedrosa, Sandra; González García, Javier; Vázquez Morón, Juan María.
Afiliação
  • Hernández Martínez A; Digestivo, Hospital Universitario Torrecárdenas, España.
  • Navajas Hernández P; Digestivo, Hospital Universitario Virgen Macarena.
  • Martín Rodríguez MDM; Digestivo, Hospital Universitario Virgen de las Nieves.
  • Lázaro Sáez M; Digestivo, Hospital Universitario Torrecárdenas.
  • Olmedo Martín R; Digestivo, Hospital Regional Universitario Carlos Haya.
  • Núñez Ortiz A; Digestivo, Hospital Universitario Virgen del Rocío, España.
  • Argüelles Arias F; Digestivo, Hospital Universitario Virgen Macarena.
  • Fernández Cano MC; Digestivo, Hospital Universtiario Virgen de las Nieves, España.
  • Gallardo Sánchez F; Digestivo, Hospital de Poniente.
  • Marín Pedrosa S; Digestivo, Hospital Universitario Reina Sofía.
  • González García J; Digestivo, Hospital La Inmaculada, España.
  • Vázquez Morón JM; Digestivo, Hospital Universitario Juan Ramón Jiménez.
Rev Esp Enferm Dig ; 114(9): 516-521, 2022 09.
Article em En | MEDLINE | ID: mdl-35000397
BACKGROUND: tofacitinib is a Janus kinase inhibitor approved for the treatment of moderate-severe ulcerative colitis (UC). This study aimed to evaluate its efficacy in a real-life setting. METHODS: a retrospective and multicenter observational study was performed with UC patients treated with tofacitinib. Short and long-term treatment effectiveness, treatment survival, need for dose escalation and safety were analyzed. Clinical response and remission were defined in accordance with the partial Mayo score. RESULTS: seventy-four patients were included, 98.3 % had received prior biological treatment, 55.4 % with three or more biologicals and up to 64.9% with two or three different mechanisms of action. Clinical remission and response rates were 37.8 % and 77 % at eight weeks, and 41.8 % and 70.1 % at 16 weeks. With regard to non-responders at eight weeks, 37.5 % achieved a delayed clinical response at 16 weeks. Mean treatment duration was 19 months (95 % CI: 16-22), with a treatment survival of 56 % at 28 months, and remission and response rates at 24 months of 53.8 % and 61.5 %. Twenty-three treatments were withdrawn, most of them (18) during the induction period. There were adverse events in a quarter of the patients; only four were severe and led to treatment discontinuation. CONCLUSION: tofacitinib has a demonstrated efficacy in clinical practice to induce and maintain clinical response in treatment-refractory UC patients, with an acceptable safety profile.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Colite Ulcerativa Tipo de estudo: Observational_studies Limite: Humans Idioma: En Revista: Rev Esp Enferm Dig Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Colite Ulcerativa Tipo de estudo: Observational_studies Limite: Humans Idioma: En Revista: Rev Esp Enferm Dig Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2022 Tipo de documento: Article